

Faculty



Chairs:

Professor the Lord Kakkar

University College London and Director of the Thrombosis Research Institute London, UK

Professor Kenneth Bauer

Beth Israel Deaconess Medical Center Boston, MA, USA

Speakers and debate participants:

Professor Gregory Lip

Haemostasis, Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences Birmingham, UK

Professor Masatsugu Hori

Osaka Medical Center for Cancer and Cardiovascular Diseases

Professor Harry Büller

Department of Vascular Medicine, Academic Medical Center, University of Amsterdam Amsterdam, The Netherlands

Professor Alexander GG Turpie

McMaster University and Hamilton Health Services Hamilton, ON, Canada

Professor Walter Ageno

Department of Clinical Medicine, University of Insubria Varese, Italy

Sponsored by Bayer HealthCare Pharmaceuticals

The marketing authorization for rivaroxaban may vary from country to country. In Japan, rivaroxaban is not currently approved for any VTE or AF indication.

© Bayer HealthCare Pharmaceuticals 2011

Long-term Anticoagulation

Debating the future

Chaired by Ajay Kakkar and Kenneth Bauer


Monday 25 July 2011, 18:15–20:15

Sakura, 1F, Kyoto International Conference Center (ICC Kyoto), Kyoto, Japan

A Satellite Symposium sponsored by Bayer HealthCare Pharmaceuticals at the XXIII Congress of the International Society on Thrombosis and Haemostasis Kyoto, Japan
23–28 July 2011



BHP/P00464 xxxxxxxxxxxxxxxx



Chairmen's Welcome

Dear Colleagues,

We are delighted to host this Satellite Symposium at the XXIII Congress of the International Society on Thrombosis and Haemostasis held this year in Kyoto. We invite you to an innovative programme focusing on long-term oral anticoagulation. Using plenary presentations and expert debates, this symposium will examine current and future approaches to stroke prevention in atrial fibrillation (AF) and treatment of venous thromboembolism (VTE).

The symposium will open with an introductory presentation on the role of anticoagulant therapy in stroke prevention in AF and the management of VTE. Continuing with this theme, Professor Gregory Lip will discuss the extensive recent clinical data evaluating the use of new oral anticoagulants in the prevention of stroke in patients with AF. The expert faculty will then participate in a debate and discussion of the current anticoagulant options available for stroke prevention in AF and the implications of these new data for patients and guidelines.

In the next session, Professor Harry Büller will summarize clinical trial data showing the role and importance of new oral anticoagulants in the treatment of VTE. Following his presentation, the expert faculty will discuss current approaches to VTE treatment on the basis of recent clinical trial results with new oral anticoagulants.

We hope that you will be able to join us for what promises to be a programme of great interest.

Kind regards,



Ajay Kakkar



Kenneth Bauer

Programme

Chaired by Ajay Kakkar and Kenneth Bauer

Monday 25 July 2011, 18:15–20:15

Sakura, 1F, Kyoto International Conference Center (ICC Kyoto), Kyoto, Japan

A Satellite Symposium sponsored by Bayer HealthCare Pharmaceuticals at the XXIII Congress of the International Society on Thrombosis and Haemostasis, 23–28 July 2011

18:15 Welcome and introduction

Ajay Kakkar, UK

18:30 Atrial fibrillation: Updates on recent therapeutic advances

Gregory Lip, UK

18:50 Debate and discussion

Gregory Lip, UK and Masatsugu Hori, Japan

19:20 VTE treatment: Updates on recent therapeutic advances

Harry Büller, The Netherlands

19:40 Debate and discussion

Harry Büller, The Netherlands; Alexander GG Turpie, Canada; and Walter Ageno, Italy

20:10 Closing remarks

Kenneth Bauer, USA

